Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative

This article was originally published in The Pink Sheet Daily

Executive Summary

With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.

You may also be interested in...



NIH Drug Repurposing Program Produces Surprise Overlaps

Crowdsourcing among researchers produces several applications proposing to test a few compounds in the NCATS repurposing library for use in multiple new indications, which officials did not expect.

Abandoned AstraZeneca Compounds “Given” To U.K. R&D Academics

AstraZeneca is giving 15 shelved compounds to U.K.-based academics in a collaboration funded by public money that may produce scientific breakthroughs along with thorny IP issues.

NCATS Opens Repurposing Project With 58 Compounds, 17 From Pfizer

The National Institutes of Health’s National Center for Accelerating Translational Science has opened the pilot round of its compound repurposing effort with 58 drug candidates that will be made available to academic researchers. Half of the 58 have failed in previous studies for neurological indications, a recognized trouble spot for drug development.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS074185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel